iTeos Therapeutics (NASDAQ:ITOS) Price Target Lowered to $15.00 at JPMorgan Chase & Co.

iTeos Therapeutics (NASDAQ:ITOS) had its price target reduced by JPMorgan Chase & Co. from $22.00 to $15.00 in a report issued on Thursday,Benzinga reports. They currently have an overweight rating on the stock.

ITOS has been the subject of a number of other research reports. Wedbush reiterated an “outperform” rating and set a $25.00 target price on shares of iTeos Therapeutics in a report on Wednesday. HC Wainwright reissued a “buy” rating and set a $46.00 price target on shares of iTeos Therapeutics in a research report on Thursday. Finally, Wells Fargo & Company reduced their price target on iTeos Therapeutics from $31.00 to $19.00 and set an “overweight” rating on the stock in a research report on Thursday, December 19th.

iTeos Therapeutics Stock Performance

Shares of NASDAQ:ITOS opened at $7.09 on Thursday. iTeos Therapeutics has a 1 year low of $6.67 and a 1 year high of $18.75. The stock has a market capitalization of $259.03 million, a P/E ratio of -2.25 and a beta of 1.38. The stock has a 50-day simple moving average of $7.53 and a 200-day simple moving average of $9.54.

iTeos Therapeutics (NASDAQ:ITOS) last issued its earnings results on Wednesday, March 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.14) by $0.13. Analysts predict that iTeos Therapeutics will post -3.49 earnings per share for the current year.

Hedge Funds Weigh In On iTeos Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of ITOS. Public Employees Retirement System of Ohio raised its position in shares of iTeos Therapeutics by 192.2% in the 4th quarter. Public Employees Retirement System of Ohio now owns 84,220 shares of the company’s stock valued at $647,000 after purchasing an additional 55,394 shares in the last quarter. Stonepine Capital Management LLC raised its position in shares of iTeos Therapeutics by 266.7% in the 4th quarter. Stonepine Capital Management LLC now owns 110,000 shares of the company’s stock valued at $845,000 after purchasing an additional 80,000 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of iTeos Therapeutics in the 4th quarter valued at approximately $42,000. Man Group plc raised its position in shares of iTeos Therapeutics by 34.7% in the 4th quarter. Man Group plc now owns 29,169 shares of the company’s stock valued at $224,000 after purchasing an additional 7,516 shares in the last quarter. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of iTeos Therapeutics by 90.5% in the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 125,589 shares of the company’s stock valued at $965,000 after purchasing an additional 59,649 shares in the last quarter. 97.16% of the stock is owned by institutional investors and hedge funds.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.